Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425826 | 0.88 | TRPV4 (0.46) | TRPV4CYP11B1CYP11B2MEN1TTR | |
| SCHEMBL21081880 | 0.85 | TRPV4 (0.45) | TRPV4KDM4EHPGD | |
| SCHEMBL1317673 | 0.84 | TRPV4 (0.43) | TRPV4CYP11B1CYP11B2KDM4EMEN1 | |
| SCHEMBL18305809 | 0.84 | TRPV4 (0.43) | TRPV4CYP11B1CYP11B2HPGDMEN1 | |
| SCHEMBL423554 | 0.84 | TRPV4 (0.43) | TRPV4CYP11B1CYP11B2EGLN2TTR | |
| SCHEMBL31113834 | 0.84 | TRPV4 (0.43) | TRPV4KDM4EHPGDNPSR1MEN1 | |
| SCHEMBL15674088 | 0.84 | TRPV4 (0.43) | TRPV4CYP11B1CYP11B2KDM4ENPSR1 | |
| SCHEMBL13868306 | 0.84 | TRPV4 (0.43) | TRPV4KDM4EHPGDNPSR1MEN1 | |
| SCHEMBL27439566 | 0.80 | TRPV4 (0.48) | TRPV4CYP11B1CYP11B2EGLN2KDM4E | |
| SCHEMBL1629238 | 0.80 | TRPV4 (0.39) | TRPV4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 631 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574068-A | Pure organic room-temperature phosphorescent material with super-long charge transfer triplet state attribute, preparation method thereof and application thereof as organic photoinitiator | 重庆沃肯新材料科技股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-117003670-B | Preparation process of 4-bromo-2, 6-difluorobenzonitrile | 杭州国瑞生物科技有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-117447384-B | Spiro heterocyclic aryl compound and application thereof | 四川大学 | 2024-12-27 | — | — | CN | claimed |
| CN-118005536-B | Ultralong thermal activation delayed fluorescence compound and preparation method and application thereof | 重庆沃肯新材料科技股份有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-118005536-A | Ultralong thermal activation delayed fluorescence compound and preparation method and application thereof | 重庆沃肯新材料科技股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117447384-A | Spiro heterocyclic aryl compound and application thereof | 四川大学 | 2024-01-26 | — | — | CN | claimed |
| CN-117003670-A | Preparation process of 4-bromo-2, 6-difluorobenzonitrile | 杭州国瑞生物科技有限公司 | 2023-11-07 | — | — | CN | claimed |
| JP-4159258-A | — | — | None | — | — | JP | disclosed |
| EP-4590675-B1 | HETEROCYCLIC SIK INHIBITORS | PFIZER (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637445-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026107227-A1 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4741389-A1 | KAT6 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026090589-A1 | HETEROCYCLIC HBS1L DEGRADERS | TANGO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2002070469-A2 | SELECTIVE PDE3B INHIBITORS AND USE OF THE SAME IN THERAPY | ICOS CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-0407438-B1 | LATERALLY FLUORINATED 4-CYANOPHENYL AND 4'-CYANOBIPHENYL BENZOATES | SECR DEFENCE BRIT (GB) | 1995-01-04 | — | — | EP | disclosed |
| US-5334327-A | Nematic liquid crystal display device | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTH IRELAND (GB) | 1994-08-02 | — | — | US | disclosed |
| US-5156763-A | Liquid crystals | THE SECRETARY OF STATE FOR FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1992-10-20 | — | — | US | disclosed |
| JP-H04159258-A | DIFLUOROBENZONITRILE DERIVATIVE AND LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME AND LIQUID CRYSTAL DISPLAY USING THE COMPOSITION | SEIKO EPSON CORP | 1992-06-02 | — | — | JP | disclosed |
| EP-0407438-A1 | LATERALLY FLUORINATED 4-CYANOPHENYL AND 4'-CYANOBIPHENYL BENZOATES. | SECR DEFENCE BRIT (GB) | 1991-01-16 | — | — | EP | disclosed |
| WO-1989008102-A1 | LATERALLY FLUORINATED 4-CYANOPHENYL AND 4'-CYANOBIPHENYL BENZOATES | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNI (GB) | 1989-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637445-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF2C | TRPV4 4110/4885CYP11B1 2632/4885CYP11B2 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.